Effects of Edaravone on Muscle Atrophy and Locomotor Function in Patients with Ischemic Stroke (a Randomized Controlled Pilot Study)
Background and Objective: Stroke patients with severe leg paralysis are often bedridden in the acute and subacute phase, which increases the risk of disuse muscle atrophy in the chronic phase. The evidence to date indicates that oxidative stress plays an important role in the mechanism of disuse muscle atrophy. Therefore, the aim of this study was […]
Posted: Drugs R D 2010; 10 (3)
Final Evaluation of the Results of the СТІКс Study (Concomitant Xavron Stroke Therapy)
Abstract. Ischemic stroke remains a pressing problem today. Its pathogenesis consists of a sequential cascade of reactions in the brain, which, in addition to ischemia, are responsible for further damage to brain tissue and slow down the development of compensatory and regenerative mechanisms. Attempts to break the pathological cascade have been going on for decades. The […]
Posted: International Neurological Journal, Volume 17, N 5, 2021
Vascular neurological complications in patients with COVID-19
The article considers modern views on the development and course of coronavirus infection COVID-19. Particular attention is paid to vascular neurological complications. Edaravone and citicoline with electrolytes were used to optimize the treatment of cerebrovascular complications in patients with concomitant COVID-19. Clinical and paraclinical data of 34 patients were analyzed. As a result, it is […]
Posted: www.umj.com.ua
Japanese Guidelines for the Management of Stroke 2015 [2017].
Edaravone, a drug with an expected neuroprotective effect, recommended as a medicine for patients with cerebral ischemic stroke (thromboembolism) (grade B).
Posted: Міжнародний неврологічний журнал, №1 (103), 2019
Соchrane Database of Systematic Rewiews. Edaravone for acute ischaemic stroke
Edaravone is a neuroprotective agent, and several studies have suggested that it may be beneficial in acute ischaemic stroke. Objectives. To assess the efficacy and safety of edaravone for acute ischaemic stroke. Main results. Authors included three trials. All three included trials were of edaravone plus another treatment compared with the other treatment alone. The dose of […]
Posted: Соchrane Database of Systematic Rewiews, 2011.
Japanese experience in the treatment of patients with acute ischemic stroke. Interview with Professor Yukito Shinohara
The Academy of Stroke, Annual Scientific and Educational Forum, traditionally dedicated to World Stroke Day was held in Kyiv October 31 – November 1, 2019. Yukito Shinohara, Professor Emeritus of Tokai University School of Medicine, former president of the Japan Stroke Society and the Asia Pacific Stroke Organization, Chairman of the Japanese Stroke Guidelines in […]
Posted: International Neurological Journal №8 (110), 2019
The use of the drug Xavron (Edaravon) in the complex treatment of patients with ischemic stroke in combination with thrombolytic therapy
Resume. The article describes the experience of the early use of Xavron (Edaravon) in patients with ischemic stroke in combination with thrombolytic therapy (TLT). These studies indicate greater efficacy of using Edaravon in combination with TLT in the treatment of ischemic stroke. When using the drug Xavron side effects of the drug was not observed.
Posted: THE JOURNAL OF NEUROSCIENCE of B.M. Mankovskyi’ 2019, ТОМ 7, № 3-4
Usage of the new edaravone free radical scavenger (XAVRON) in the treatment of acute ischemic stroke
The purpose of the study is to evaluate the effectiveness of use of the drug edaravone for treatment of patients with acute cerebral infarction comparing to citicoline. The results of the treatment of ischemic stroke by intravenous administration of edaravone (Xavron) and citicoline indicated a more pronounced elimination of neurological deficit in the group edaravone.
Posted: МЛ №1-2 (157-158) 2019
Perspective Treatment Goals for Brain Protection in Case of Acute Ischemia
Abstract. Ischemic stroke initiates a cascade of biochemical reactions, among which the processes of free radical oxidation occupy a key place. The most important place in management this disease takes reperfusion therapy, the conduct of which is closely related to the problem of neuroprotection. Use of antioxidants is a promising direction for the treatment of ischemic […]
Posted: Infusion & Chemotherapy № 2, 2019
Brain protection in acute ischemia
From 15 to 16 million people suffer a stroke every year, of which 100-110 thousand are residents of Ukraine. This vascular desiase ranks first among causes of disability and is one of the leading causes of death. One third of patients die during the first year after stroke, one out of four becomes disabled with […]
Posted: Medical newspaper “Health of Ukraine. Neurology, Psychiatry, Psychotherapy”, No 3 (50), October 2019
Japan’s striking success in fighting stroke: review by Prof. Yukito Shinohara in Ukraine, 2019
Neurologist from Japan visits Ukraine for the first time. Dr. Yukito Shinohara is Immediate Past President of the Japan Stroke Society and the Asia Pacific Stroke Organization. He was Chairman of the Japanese Stroke Guidelines in 2004 and 2009. Professor Shinohara gave a presentation on theme “Present Stroke Situation in Japan and Japanese Stroke Guidelines” […]
First experience of using Xavron, a free radical scavenger, in patients with acute ischemic stroke
Abstract. Background. In acute ischemic stroke (AIS), more than 1,000 substances with known neuroprotective effects have been studied, but their effectiveness is considered insufficiently convincing. In 2018, Ukraine launched the release of a new free radical scavenger Xavron (active ingredient — edaravone), which since 2001 has been successfully prescribed in Japan for the treatment of AIS and […]
Posted: Emergency medicine № 3 (98), 2019